Clinical Trials Browser

Phase 2 × Temozolomide × Breast × Clear all

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT01009788 2025-03-14

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Phase 2 Completed

63 enrolled 11 charts

Breast Neoplasms

NCT00617539 2018-04-20

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

Phase 2 Completed

30 enrolled 10 charts

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00638963 2017-06-14

STOP

Phase 2 Terminated

6 enrolled 9 charts

Brain Neoplasms, Breast Neoplasms, Neoplasms, Second Primary

NCT00831545 2017-05-09

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

Phase 2 Completed

BreastDermatologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00005054 2013-09-20

Temozolomide in Treating Women With Advanced Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00875355 2009-08-26

Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer

Phase 2 Unknown

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

NCT00194766 2007-11-14

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Sarcoma